Review
Gastroenterology & Hepatology
Uday C. Ghoshal
Summary: Postinfection IBS (PI-IBS) is a subset of patients developing new onset IBS following acute gastroenteritis, with a prevalence rate of 11.5%. Various factors are associated with the development of PI-IBS, suggesting a potential organic basis. More studies are needed to explore the treatment of PI-IBS, as randomized controlled trials are rare.
Article
Biochemistry & Molecular Biology
Sholpan Omarova, Karem Awad, Verena Moos, Christoph Puening, Greta Goelz, Jorg-Dieter Schulzke, Roland Buecker
Summary: This study observed patients with persistent PI-IBS symptoms after C. jejuni infection and found that the epithelial resistance of the colon epithelium was unaltered, but the permeability of HRP increased and some inflammation-related markers were elevated. Therefore, targeting these mechanisms caused by the infection may help reduce sequelae such as PI-IBS.
Review
Gastroenterology & Hepatology
Lucas Guillo, Ferdinando D'Amico, Silvio Danese, Laurent Peyrin-Biroulet
Summary: Ustekinumab has shown effectiveness in treating EIMs, especially for dermatological and rheumatological manifestations, but more data are needed to confirm its role in this setting.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Gastroenterology & Hepatology
Nikita Hanning, Adam L. Edwinson, Hannah Ceuleers, Stephanie A. Peters, Joris G. De Man, Leslie C. Hassett, Benedicte Y. De Winter, Madhusudan Grover
Summary: Barrier dysfunction is present in a significant proportion of adult and all pediatric IBS studies, especially in the IBS-D and PI-IBS subtype. The majority of studies indicated a positive association between loss of barrier function and symptoms such as abdominal pain and changes in the bowel function.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2021)
Review
Medicine, General & Internal
Aliya H. Sange, Natasha Srinivas, Mubashira K. Sarnaik, Srimy Modi, Yasaswi Pisipati, Sarayoo Vaidya, Naqvi Syed Gaggatur, Ibrahim Sange
Summary: Inflammatory bowel disease (IBD) is closely associated with extra-intestinal manifestations (EIMs) that have a negative impact on quality of life. Research shows that EIMs are closely linked to intestinal inflammation, but can also occur independently and require different management methods. Understanding the etiology, pathogenic mechanisms, epidemiology, clinical features, and treatment of EIMs is crucial.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Article
Medicine, General & Internal
Francesca Ferretti, Maria Camilla Monico, Rosanna Cannatelli, Stefania Carmagnola, Marco Vincenzo Lenti, Antonio Di Sabatino, Francesco Conforti, Luca Pastorelli, Flavio Caprioli, Cristina Bezzio, Simone Saibeni, Stefano Mazza, Maurizio Vecchi, Giovanni Maconi, Sandro Ardizzone
Summary: This study suggests that the type of biologic treatment may affect the risk of developing extra-intestinal manifestations in patients with inflammatory bowel disease. There is a slightly higher risk in patients on gut-selective therapies, but the clinical course is similar in both groups.
FRONTIERS IN MEDICINE
(2022)
Review
Gastroenterology & Hepatology
Yizhe Tie, Yongle Huang, Rirong Chen, Li Li, Minhu Chen, Shenghong Zhang
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, and patients with IBD may also experience extra-intestinal manifestations (EIMs). This review discusses the potential involvement of the gut microbiota in the pathogenesis of EIMs, including impaired gut barrier, microbial translocation, molecular mimicry, dysregulation of microbiota-related metabolites, and activation of immunocytes and release of pro-inflammatory cytokines. The review also summarizes microbiota-related therapies for better management of IBD-associated EIMs.
Review
Medicine, General & Internal
Mihaela Fadgyas Stanculete, Abdulrahman Ismaiel, Stefan-Lucian Popa, Octavia Oana Capatina
Summary: Irritable bowel syndrome (IBS) is a disorder characterized by altered gut-brain interaction and dysfunction of the brain-gut-microbiota axis. Prior studies have shown significant impairments in the health-related quality of life of patients with IBS. Resilience, as a psychosocial ability, plays a crucial role in promoting health and enhancing stress response.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Xiao Jing Wang, Jon O. Ebbert, Connor G. Loftus, Jordan K. Rosedahl, Lindsey M. Philpot
Summary: This study investigated the relationship between central sensitization syndrome (CSS) diagnoses, quality of life, symptom severity, and interactions with healthcare providers in rural community populations. The findings showed that patients with IBS often have multiple CSS disorders, which increases symptom severity and lowers quality of life. Therefore, treating multiple CSS diagnoses as a global condition may improve patient experience.
NEUROGASTROENTEROLOGY AND MOTILITY
(2023)
Article
Gastroenterology & Hepatology
Madhusudan Grover, Antonio Berumen, Stephanie Peters, Ting Wei, Margaret Breen-Lyles, William S. Harmsen, Irene Busciglio, Duane Burton, Maria Vazquez Roque, Kenneth R. DeVault, Michael Camilleri, Michael Wallace, Surendra Dasari, Helmut Neumann, Lesley A. Houghton
Summary: This study found that patients with irritable bowel syndrome (IBS) had a stronger symptom response to small intestinal lipid infusion, which was associated with the expression of TRPV channels, suggesting that TRPV-mediated small intestinal chemosensitivity may play a role in post-meal symptoms in IBS.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Gastroenterology & Hepatology
Maeva Meynier, Elodie Baudu, Nathalie Rolhion, Manon Defaye, Marjolene Straube, Valentine Daugey, Morgane Modoux, Ivan Wawrzyniak, Frederic Delbac, Romain Villeger, Mathieu Meleine, Esther Borras Nogues, Catherine Godfraind, Nicolas Barnich, Denis Ardid, Philippe Poirier, Harry Sokol, Jean-Marc Chatel, Philippe Langella, Valerie Livrelli, Mathilde Bonnet, Frederic Antonio Carvalho
Summary: This study explores the relationship between brain/gut/microbiota axis and Irritable Bowel Syndrome (IBS), focusing on tryptophan metabolism and microbiota-induced AhR expression. The results show that IL-22 cytokine can alleviate post-infectious IBS symptoms such as colonic hypersensitivity, cognitive impairments, and anxiety-like behaviors, by acting on intestinal mucosa integrity. Therapeutic strategies targeting this pathway could potentially be developed for the treatment of IBS patients suffering from chronic abdominal pain and associated well-being disorders.
Article
Microbiology
Jonathan P. P. Jacobs, Venu Lagishetty, Megan C. C. Hauer, Jennifer S. S. Labus, Tien S. S. Dong, Ryan Toma, Momchilo Vuyisich, Bruce D. D. Naliboff, Jeffrey M. M. Lackner, Arpana Gupta, Kirsten Tillisch, Emeran A. A. Mayer
Summary: This study used multi-omics assessment methods to explore the changes in gut microbiome function in irritable bowel syndrome (IBS), and identified new microbial biomarkers. The findings support the application of integrated assessment of microbial function in IBS research, and contribute to the discovery of novel microbiome-related therapeutic targets.
Review
Biochemistry & Molecular Biology
Emeran A. Mayer, Hyo Jin Ryu, Ravi R. Bhatt
Summary: Irritable bowel syndrome (IBS) is a prevalent disorder of brain-gut interactions, affecting 5-10% of the global population. The current diagnosis criteria focus on recurrent abdominal pain and altered bowel habits, but patients also experience non-painful abdominal discomfort, psychiatric conditions, and other pain-related symptoms. Recent research has revealed a comprehensive disease model of brain-gut-microbiome interactions, explaining the various symptoms of IBS. This model incorporates the gut connectome, enteric nervous system, brain alterations, and correlations with genetic, gastrointestinal, immune, and gut microbiome-related factors.
MOLECULAR PSYCHIATRY
(2023)
Article
Gastroenterology & Hepatology
Katherine Falloon, Benjamin Cohen, Ashwin N. Ananthakrishnan, Edward L. Barnes, Abhik Bhattacharya, Jean-Frederic Colombel, Raymond K. Cross, Marcia S. Driscoll, Anthony P. Fernandez, Christina Ha, Hans Herfarth, Sara Horst, Jason Hou, M. Elaine Husni, Daniela Kroshinsky, Kristine A. Kuhn, Careen Y. Lowder, George Martin, Deep Parikh, Christopher J. Sayed, Lisa Schocket, Bernadette C. Siaton, Priyanka Vedak, Michael H. Weisman, Florian Rieder
Summary: An interdisciplinary expert panel developed consensus criteria for diagnosing and monitoring five EIMs, providing guidance for clinical practice and future trial design. Key findings include straightforward diagnostic criteria, appropriate specialists for diagnosis, and monitoring options that include patient and physician-reported outcomes. These criteria will be used to optimize the management of EIMs in a national multicenter study network.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Gastroenterology & Hepatology
Bodil Ohlsson
Summary: Irritable bowel syndrome (IBS) patients often experience extraintestinal manifestations in addition to gastrointestinal symptoms. These manifestations are associated with worse suffering and difficulties in treating symptoms. Evaluation and treatment of IBS patients should consider these extraintestinal manifestations and their treatment outcomes.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2022)